Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiometabolic and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SREBF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SREBF1 Recombinant Active Domain Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for DNA-binding assays. |
View SREBF1 Products |
| Gene Delivery | SREBF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and nuclear translocation assays. |
View SREBF1 Products |
| Benchmark Ab | Anti-SREBF1 Recombinant Antibody Sequence-verified positive control for Western Blot and IHC. |
View SREBF1 Products |
| Validator | SREBF1 siRNA Set For knockdown verification in lipogenesis assays. |
View SREBF1 Products |
| Related Target A | SREBF2 Key transcription factor for cholesterol homeostasis; essential for selectivity counter-screening. |
View SREBF2 Products |
| Related Target B | FASN Direct downstream target of SREBF1; critical biomarker for functional validation. |
View FASN Products |
| Related Target C | SCD1 Rate-limiting lipogenic enzyme regulated by SREBF1; indicator of therapeutic efficacy. |
View SCD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Transcription Factor Targeting | Lentivirus-mediated overexpression of full-length SREBF1 for robust nuclear translocation and reporter assays. |
| SREBF1 vs SREBF2 Selectivity Screening | Highly purified recombinant active domains of both SREBF1 and SREBF2 for parallel DNA-binding specificity assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Lipogenesis Assays | High-purity, endotoxin-controlled reagents to prevent non-specific inflammatory-induced lipid accumulation |
Live SREBF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SREBF1 therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic inhibition to tissue-specific and tumor-targeted modalities. SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1) serves as a master regulator of de novo lipogenesis, making it a highly prized target in both metabolic dysfunction-associated steatohepatitis (MASH/NASH) and lipid-dependent oncology indications, such as glioblastoma and prostate cancer.
As first-generation direct transcription factor inhibitors face specificity challenges, the next wave of R&D is targeting upstream regulators (e.g., SCAP, S1P/S2P proteases) or utilizing advanced RNA therapeutics (siRNA/ASO) and targeted protein degradation (PROTACs) to achieve tissue-selective SREBF1 downregulation without triggering systemic hypercholesterolemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SCAP/SREBP Inhibitors) | HepaRegeniX, Sagimet Biosciences | MASH / NASH, Solid Tumors | Selectivity Assay (Need SREBF1 vs SREBF2 recombinant proteins) |
| siRNA / ASO | Alnylam Pharmaceuticals, Ionis Pharmaceuticals | Hyperlipidemia, Fatty Liver Disease | Knockdown Validation (Need validated siRNA and Lentivirus tools) |
| PROTAC / Degraders | Arvinas, Kymera Therapeutics | Oncology (Prostate, Breast Cancer) | Degradation & Expression Kinetics (Need high-purity SREBF1 antibodies for Western Blot) |